

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Trastuzumab deruxtecan for treating HER2-low unresectable or metastatic breast cancer after chemotherapy (ID3935)

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

| |
|--|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
| One stakeholder expressed concerns regarding the use of the severity modifier which categorises patients by age when determining the absolute and to a lesser extent the proportionate shortfall. “Metastatic breast cancer is the largest cause of death in women aged 35-50 years and while it decreases the life expectancy of the average person, the use of discounting at 3.5% and quality adjusted life expectancy may fail to capture this. It is unclear whether the severity modifier captures the actual loss of life years at a level comparable to the end-of-life criteria it has replaced.” |
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
| The committee would need to consider the severity modifier and whether people are disadvantaged because of the age group. |
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
| No. |

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No.

Approved by Associate Director (name):Janet Robertson.....

Date: 05 January 2023